Alpha-1 Blocker - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Alpha-1 Blocker

The Experts below are selected from a list of 5607 Experts worldwide ranked by ideXlab platform

Alpha-1 Blocker – Free Register to Access Experts & Abstracts

P Pacifico – One of the best experts on this subject based on the ideXlab platform.

  • effects of short term treatment with the alpha 1 Blocker alfuzosin on urodynamic pressure flow parameters in patients with benign prostatic hyperplasia
    European Urology, 1997
    Co-Authors: Giuseppe Martorana, C Giberti, F Di Silverio, M Von Heland, Patrizio Rigatti, R Colombo, G Casadei, P Pacifico

    Abstract:

    OBJECTIVE: The objective of this double-blind, placebo-controlled urodynamic pressure/flow study was to assess the efficacy of short-term treatment with the alpha 1-Blocker alfuzosin in outflow obstruction of patients with symptomatic benign prostatic hyperplasia (BPH). MATERIAL AND METHODS: Urodynamic pressure/flow parameters were assessed after 2 weeks of placebo run-in, 4 weeks of placebo (47 patients) or 2.5 mg t.i.d. alfuzosin treatment (47 patients), followed by an 8-week extension period with alfuzosin (single-blind). RESULTS AND CONCLUSION: Four weeks of alfuzosin treatment significantly increased maximum flow (+29.0%) and decreased detrusor pressure at maximum flow (-30.2%), detrusor opening pressure (-39.4%) and maximum detrusor pressure (-28.7%). Short-term alfuzosin treatment improved outflow conditions in BPH by reducing prostatic urethral obstruction.

  • Effects of short-term treatment with the alpha 1-Blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    European urology, 1997
    Co-Authors: Giuseppe Martorana, C Giberti, F Di Silverio, Patrizio Rigatti, R Colombo, G Casadei, M. Von Heland, P Pacifico

    Abstract:

    OBJECTIVE The objective of this double-blind, placebo-controlled urodynamic pressure/flow study was to assess the efficacy of short-term treatment with the alpha 1-Blocker alfuzosin in outflow obstruction of patients with symptomatic benign prostatic hyperplasia (BPH). MATERIAL AND METHODS Urodynamic pressure/flow parameters were assessed after 2 weeks of placebo run-in, 4 weeks of placebo (47 patients) or 2.5 mg t.i.d. alfuzosin treatment (47 patients), followed by an 8-week extension period with alfuzosin (single-blind). RESULTS AND CONCLUSION Four weeks of alfuzosin treatment significantly increased maximum flow (+29.0%) and decreased detrusor pressure at maximum flow (-30.2%), detrusor opening pressure (-39.4%) and maximum detrusor pressure (-28.7%). Short-term alfuzosin treatment improved outflow conditions in BPH by reducing prostatic urethral obstruction.

Tengfu Hsieh – One of the best experts on this subject based on the ideXlab platform.

  • Alpha-1 Blocker use increased risk of subsequent renal cell carcinoma: A nationwide population-based study in Taiwan.
    PloS one, 2020
    Co-Authors: Shian-ying Sung, Tengfu Hsieh, Jin Hua Chen, Chia Ling Hsieh

    Abstract:

    Elevated Renal cell carcinoma (RCC) risk has been associated with the use of several antihypertensive medications but has not yet been elucidated in the populations prescribed Alpha-1 Blockers that are commonly used in the treatment of hypertension and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS-BPH). The aim of the present study was to investigate the association between Alpha-1 Blocker use and the risk of developing RCC using a nationwide population-based database in Taiwan. Patients who were treated with Alpha-1 Blockers for at least 28 days were identified through the Taiwan National Health Insurance Research Database from 2000 to 2010. The unexposed participants were matched with the exposed cases according to age, sex, and index year at a ratio of 3:1. Cox proportional hazards regression, stratified by sex and comorbidities and adjusted for age, was performed to estimate hazard ratios (HRs) for the risk of subsequent RCC. Among 2,232,092 subjects, patients who received Alpha-1 Blocker treatment had a higher risk of RCC than the unexposed group. Taking into account hypertension and BPH, the adjusted HR was significantly higher in male Alpha-1 Blocker users who had no BPH and either the presence (HR: 1.63, 95% confidence interval [CI] = 1.22-2.18) or absence (HR: 2.31, 95% CI = 1.40-3.81) of hypertension than in men not receiving these drugs. Taken together, male Alpha-1 Blocker users who had no comorbidity of BPH exhibited an increased risk for developing RCC independent of hypertension. Further study is warranted to elucidate the underlying mechanisms of this association.

  • maximum urine flow rate of less than 15ml sec increasing risk of urine retention and prostate surgery among patients with alpha 1 Blockers a 10 year follow up study
    PLOS ONE, 2016
    Co-Authors: Tsunghsun Tsai, Tengfu Hsieh

    Abstract:

    Background
    The aim of this study was to determine the subsequent risk of acute urine retention and prostate surgery in patients receiving Alpha-1 Blockers treatment and having a maximum urinary flow rate of less than 15ml/sec.

    Methods
    We identified patients who were diagnosed with benign prostate hyperplasia (BPH) and had a maximum uroflow rate of less than 15ml/sec between 1 January, 2002 to 31 December, 2011 from Taiwan’s National Health Insurance Research Database into study group (n = 303). The control cohort included four BPH/LUTS patients without 5ARI used for each study group, randomly selected from the same dataset (n = 1,212). Each patient was monitored to identify those who subsequently developed prostate surgery and acute urine retention.

    Results
    Prostate surgery and acute urine retention are detected in 5.9% of control group and 8.3% of study group during 10-year follow up. Compared with the control group, there was increase in the risk of prostate surgery and acute urine retention in the study group (HR = 1.83, 95% CI: 1.16 to 2.91) after adjusting for age, comorbidities, geographic region and socioeconomic status.

    Conclusions
    Maximum urine flow rate of less than 15ml/sec is a risk factor of urinary retention and subsequent prostate surgery in BPH patients receiving Alpha-1 Blocker therapy. This result can provide a reference for clinicians.

  • Maximum Urine Flow Rate of Less than 15ml/Sec Increasing Risk of Urine Retention and Prostate Surgery among Patients with Alpha-1 Blockers: A 10-Year Follow Up Study.
    PLOS ONE, 2016
    Co-Authors: Tsunghsun Tsai, Tengfu Hsieh

    Abstract:

    Background
    The aim of this study was to determine the subsequent risk of acute urine retention and prostate surgery in patients receiving Alpha-1 Blockers treatment and having a maximum urinary flow rate of less than 15ml/sec.

    Methods
    We identified patients who were diagnosed with benign prostate hyperplasia (BPH) and had a maximum uroflow rate of less than 15ml/sec between 1 January, 2002 to 31 December, 2011 from Taiwan’s National Health Insurance Research Database into study group (n = 303). The control cohort included four BPH/LUTS patients without 5ARI used for each study group, randomly selected from the same dataset (n = 1,212). Each patient was monitored to identify those who subsequently developed prostate surgery and acute urine retention.

    Results
    Prostate surgery and acute urine retention are detected in 5.9% of control group and 8.3% of study group during 10-year follow up. Compared with the control group, there was increase in the risk of prostate surgery and acute urine retention in the study group (HR = 1.83, 95% CI: 1.16 to 2.91) after adjusting for age, comorbidities, geographic region and socioeconomic status.

    Conclusions
    Maximum urine flow rate of less than 15ml/sec is a risk factor of urinary retention and subsequent prostate surgery in BPH patients receiving Alpha-1 Blocker therapy. This result can provide a reference for clinicians.

Giuseppe Martorana – One of the best experts on this subject based on the ideXlab platform.

  • effects of short term treatment with the alpha 1 Blocker alfuzosin on urodynamic pressure flow parameters in patients with benign prostatic hyperplasia
    European Urology, 1997
    Co-Authors: Giuseppe Martorana, C Giberti, F Di Silverio, M Von Heland, Patrizio Rigatti, R Colombo, G Casadei, P Pacifico

    Abstract:

    OBJECTIVE: The objective of this double-blind, placebo-controlled urodynamic pressure/flow study was to assess the efficacy of short-term treatment with the alpha 1-Blocker alfuzosin in outflow obstruction of patients with symptomatic benign prostatic hyperplasia (BPH). MATERIAL AND METHODS: Urodynamic pressure/flow parameters were assessed after 2 weeks of placebo run-in, 4 weeks of placebo (47 patients) or 2.5 mg t.i.d. alfuzosin treatment (47 patients), followed by an 8-week extension period with alfuzosin (single-blind). RESULTS AND CONCLUSION: Four weeks of alfuzosin treatment significantly increased maximum flow (+29.0%) and decreased detrusor pressure at maximum flow (-30.2%), detrusor opening pressure (-39.4%) and maximum detrusor pressure (-28.7%). Short-term alfuzosin treatment improved outflow conditions in BPH by reducing prostatic urethral obstruction.

  • Effects of short-term treatment with the alpha 1-Blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    European urology, 1997
    Co-Authors: Giuseppe Martorana, C Giberti, F Di Silverio, Patrizio Rigatti, R Colombo, G Casadei, M. Von Heland, P Pacifico

    Abstract:

    OBJECTIVE The objective of this double-blind, placebo-controlled urodynamic pressure/flow study was to assess the efficacy of short-term treatment with the alpha 1-Blocker alfuzosin in outflow obstruction of patients with symptomatic benign prostatic hyperplasia (BPH). MATERIAL AND METHODS Urodynamic pressure/flow parameters were assessed after 2 weeks of placebo run-in, 4 weeks of placebo (47 patients) or 2.5 mg t.i.d. alfuzosin treatment (47 patients), followed by an 8-week extension period with alfuzosin (single-blind). RESULTS AND CONCLUSION Four weeks of alfuzosin treatment significantly increased maximum flow (+29.0%) and decreased detrusor pressure at maximum flow (-30.2%), detrusor opening pressure (-39.4%) and maximum detrusor pressure (-28.7%). Short-term alfuzosin treatment improved outflow conditions in BPH by reducing prostatic urethral obstruction.